Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 7/2016

05.12.2015 | Original Article

Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases

verfasst von: Aurélien Archier, Arthur Varoquaux, Philippe Garrigue, Marion Montava, Carole Guerin, Sophie Gabriel, Eva Beschmout, Isabelle Morange, Nicolas Fakhry, Frédéric Castinetti, Frédéric Sebag, Anne Barlier, Anderson Loundou, Benjamin Guillet, Karel Pacak, David Taïeb

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pheochromocytomas/paragangliomas (PHEOs/PGLs) overexpress somatostatin receptors and recent studies have already shown excellent results in the localization of these tumors using 68Ga-labeled somatostatin analogs (68Ga-DOTA-SSA), especially in patients with germline succinate dehydrogenase subunit B gene (SDHB) mutations and head and neck PGLs (HNPGLs). The value of 68Ga-DOTA-SSA has to be established in sporadic cases, including PHEOs. Thus, the aim of this study was to compare 68Ga-DOTATATE PET/CT, 18F-FDOPA PET/CT, and conventional imaging in patients with various PHEOs/PGLs with a special emphasis on sporadic cases, including those located in the adrenal gland.

Design

68Ga-DOTATATE, 18F-FDOPA PET/CT, and conventional imaging (contrast-enhanced CT and MRI with MR angiography sequences) were prospectively performed in 30 patients (8 with SDHD mutations, 1 with a MAX mutation and 21 sporadic cases) with PHEO/PGL at initial diagnosis or relapse.

Results

The patient-based sensitivities were 93 % (28/30), 97 % (29/30), and 93 % (28/30) for 68Ga-DOTATATE PET/CT, 18F-FDOPA PET/CT, and conventional imaging, respectively. The lesion-based sensitivities were 93 % (43/46), 89 % (41/46), and 76 % (35/46) for 68Ga-DOTATATE PET/CT, 18F-FDOPA PET/CT, and conventional imaging respectively (p = 0.042). 68Ga-DOTATATE PET/CT detected a higher number of HNPGLs (30/30) than 18F-FDOPA PET/CT (26/30; p = 0.112) and conventional imaging (24/30; p = 0.024). 68Ga-DOTATATE PET/CT missed two PHEOs of a few millimeters in size and a large recurrent PHEO. One lesion was considered false-positive on 68Ga-DOTATATE PET/CT and corresponded to a typical focal lesion of fibrous dysplasia on MRI. Among the 11 lesions missed by conventional imaging, 7 were detected by conventional imaging with knowledge of the PET results (4 HNPGLs, 2 LNs, and 1 recurrent PHEO).

Conclusion

68Ga-DOTATATE PET/CT is the most sensitive tool in the detection of HNPGLs, especially SDHD-related tumors, which may be very small and fail to concentrate sufficient 18F-FDOPA. The present study further expands the use of 68Ga-DOTATATE for all patients with HNPGLs, regardless of their genotype. 68Ga-DOTATATE PET/CT may be inferior to 18F-FDOPA PET/CT in the detection PHEOs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D. 15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015;22:T135–45. doi:10.1530/ERC-15-0175.CrossRefPubMed Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D. 15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015;22:T135–45. doi:10.​1530/​ERC-15-0175.CrossRefPubMed
5.
Zurück zum Zitat Neves F, Huwart L, Jourdan G, Reizine D, Herman P, Vicaut E, et al. Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol. 2008;29:883–9. doi:10.3174/ajnr.A0948.CrossRefPubMed Neves F, Huwart L, Jourdan G, Reizine D, Herman P, Vicaut E, et al. Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol. 2008;29:883–9. doi:10.​3174/​ajnr.​A0948.CrossRefPubMed
6.
Zurück zum Zitat Gravel G, Niccoli P, Rohmer V, Moulin G, Borson-Chazot F, Rousset P, et al. The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators. Eur Radiol. 2015. doi:10.1007/s00330-015-4024-5.PubMed Gravel G, Niccoli P, Rohmer V, Moulin G, Borson-Chazot F, Rousset P, et al. The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators. Eur Radiol. 2015. doi:10.​1007/​s00330-015-4024-5.PubMed
10.
Zurück zum Zitat Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42:33–41. doi:10.1007/s00259-014-2892-6.CrossRefPubMed Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42:33–41. doi:10.​1007/​s00259-014-2892-6.CrossRefPubMed
12.
Zurück zum Zitat Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16. doi:10.1148/rg.352140164.CrossRefPubMed Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16. doi:10.​1148/​rg.​352140164.CrossRefPubMed
13.
Zurück zum Zitat Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between (68)Ga-DOTA-TOC PET/CT and (18)F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40:1800–8. doi:10.1007/s00259-013-2548-y.CrossRefPubMed Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between (68)Ga-DOTA-TOC PET/CT and (18)F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40:1800–8. doi:10.​1007/​s00259-013-2548-y.CrossRefPubMed
14.
Zurück zum Zitat Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888–95. doi:10.1158/1078-0432.CCR-14-2751.CrossRefPubMed Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888–95. doi:10.​1158/​1078-0432.​CCR-14-2751.CrossRefPubMed
15.
Zurück zum Zitat Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared to other functional imaging modalities and CT/MRI. J Nucl Med. 2015. doi:10.2967/jnumed.115.161018.PubMedCentral Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared to other functional imaging modalities and CT/MRI. J Nucl Med. 2015. doi:10.​2967/​jnumed.​115.​161018.PubMedCentral
16.
Zurück zum Zitat Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol. 2011;74:21–9. doi:10.1111/j.1365-2265.2010.03893.x.CrossRef Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol. 2011;74:21–9. doi:10.​1111/​j.​1365-2265.​2010.​03893.​x.CrossRef
17.
Zurück zum Zitat King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779–85. doi:10.1210/jc.2011-0333.CrossRefPubMedPubMedCentral King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779–85. doi:10.​1210/​jc.​2011-0333.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Gabriel S, Blanchet EM, Sebag F, Chen CC, Fakhry N, Deveze A, et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18)F-FDOPA PET: focus on missed lesions. Clin Endocrinol. 2013;79:170–7. doi:10.1111/cen.12126.CrossRef Gabriel S, Blanchet EM, Sebag F, Chen CC, Fakhry N, Deveze A, et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18)F-FDOPA PET: focus on missed lesions. Clin Endocrinol. 2013;79:170–7. doi:10.​1111/​cen.​12126.CrossRef
19.
Zurück zum Zitat Chen CC, Czerwiec FS, Feuillan PP. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med. 1998;39:238–40.PubMed Chen CC, Czerwiec FS, Feuillan PP. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med. 1998;39:238–40.PubMed
21.
Zurück zum Zitat Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone. 2014;64:222–7. doi:10.1016/j.bone.2014.04.016.CrossRefPubMed Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone. 2014;64:222–7. doi:10.​1016/​j.​bone.​2014.​04.​016.CrossRefPubMed
22.
Zurück zum Zitat Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800–10.CrossRefPubMed Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800–10.CrossRefPubMed
23.
Zurück zum Zitat Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922–30.CrossRefPubMed Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922–30.CrossRefPubMed
25.
Zurück zum Zitat Saveanu A, Muresan M, De Micco C, Taieb D, Germanetti AL, Sebag F, et al. Expression of somatostatin receptors, dopamine D(2) receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:287–300. doi:10.1530/ERC-10-0175.CrossRefPubMed Saveanu A, Muresan M, De Micco C, Taieb D, Germanetti AL, Sebag F, et al. Expression of somatostatin receptors, dopamine D(2) receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:287–300. doi:10.​1530/​ERC-10-0175.CrossRefPubMed
26.
Zurück zum Zitat Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23. doi:10.1007/s00259-012-2309-3.CrossRefPubMed Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23. doi:10.​1007/​s00259-012-2309-3.CrossRefPubMed
27.
Zurück zum Zitat Huang YT, Aziz SI, Ravi Kumar AS. Gallium-68 DOTA-TATE positron emission tomography/computed tomography: scintigraphic changes of adrenal glands following management of ectopic Cushing's syndrome by steroidogenesis inhibitors. World J Nucl Med. 2014;13:201–4. doi:10.4103/1450-1147.144823.CrossRefPubMedPubMedCentral Huang YT, Aziz SI, Ravi Kumar AS. Gallium-68 DOTA-TATE positron emission tomography/computed tomography: scintigraphic changes of adrenal glands following management of ectopic Cushing's syndrome by steroidogenesis inhibitors. World J Nucl Med. 2014;13:201–4. doi:10.​4103/​1450-1147.​144823.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Blanchet EM, Millo C, Martucci V, Maass-Moreno R, Bluemke DA, Pacak K. Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol. Clin Nucl Med. 2014;39:243–50. doi:10.1097/RLU.0000000000000289.CrossRefPubMed Blanchet EM, Millo C, Martucci V, Maass-Moreno R, Bluemke DA, Pacak K. Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol. Clin Nucl Med. 2014;39:243–50. doi:10.​1097/​RLU.​0000000000000289​.CrossRefPubMed
Metadaten
Titel
Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases
verfasst von
Aurélien Archier
Arthur Varoquaux
Philippe Garrigue
Marion Montava
Carole Guerin
Sophie Gabriel
Eva Beschmout
Isabelle Morange
Nicolas Fakhry
Frédéric Castinetti
Frédéric Sebag
Anne Barlier
Anderson Loundou
Benjamin Guillet
Karel Pacak
David Taïeb
Publikationsdatum
05.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3268-2

Weitere Artikel der Ausgabe 7/2016

European Journal of Nuclear Medicine and Molecular Imaging 7/2016 Zur Ausgabe